Shilajit D Kundu

Dr. Shilajit D Kundu serves as Professor of Urology and Chief of Urologic Oncology at Northwestern University Feinberg School of Medicine, holding the Samar Kumar Kundu Professorship. His clinical expertise spans bladder cancer, prostate cancer, kidney cancer, and testicular cancer with specialization in robotic surgery and multimodal therapeutic approaches.

Education:

• MD, University of Illinois, Chicago (2001)
• Residency, Northwestern University, McGaw Medical Center (2007)
• Fellowship, Memorial Sloan Kettering Cancer Center (2009)
• Society of Urologic Oncology Fellowship, Memorial Sloan Kettering Cancer Center (2010)

Dr. Kundu's research integrates clinical urologic oncology with psychosocial and genetic investigations. He examines how patient personality, physician-patient relationships, and healthcare environments influence treatment satisfaction, while leading genetic studies to uncover prostate cancer mechanisms in inflammatory bowel disease (IBD) patients. His work bridges molecular analysis with patient-centered outcomes to optimize cancer care pathways.

Recent publications reveal evolving trends toward health disparity research (particularly in Black men's prostate cancer screening), immunosuppression-related malignancy risks, and precision surgical outcomes for renal cancers. His scholarly output demonstrates increasing focus on interdisciplinary collaboration between urology, immunology, and behavioral sciences.

Scientific Awards:

• Vincent O' Connor Teaching Award (2023)
• Chicago Magazine Top Doctors designation (2021-2022)
• Three-time Outstanding Teacher Award recipient (2018-2021)
• Chicago Urologic Society Huggins Essay Contest 1st place (2018-2019)
• Early-career research awards from India Medical Association (1997)
• Thomas O. Sidebottom Award for senior thesis (1996)

Dr. Kundu mentors medical students and residents through Northwestern's urology program, evidenced by multiple teaching accolades. He leads active clinical trials including NCT03558048 investigating IBD flares' impact on prostate-specific antigen levels, with goals to refine prostate cancer screening protocols for IBD patients and reduce unnecessary healthcare utilization.

As Chief of Urologic Oncology, he directs a multidisciplinary team within the Department of Urology while maintaining affiliations with the Robert H. Lurie Comprehensive Cancer Center, Institute for Augmented Intelligence in Medicine, and Center for Reproductive Science. His leadership extends to national committees including the American College of Surgeons Operative Standards for Cancer Surgery and North Central Section of the American Urological Association Board of Directors.